High Performance Active Pharmaceutical Ingredients (HPAPI) Market Analysis: By Ingredient 2021 | IndustryARC
  • 1-614-588-8538 (Ext: 101)
  • US Toll Free

High performance active pharmaceutical ingredients (HPAPI) Market
High Performance Active Pharmaceutical Ingredients (HPAPI) Market: By Ingredient (Synthetic, Biological and Others); By Type of Drug (Innovative, Generic, Others) By Application (Oncology, Glaucoma, Hormonal, Others) & By Geography– Forecast (2016-2021)
Report Code : CMR 0333
Published: 10 March, 2016  

  • Report Description
  • Table of Contents
  • Customization Options
The active ingredient of a pharmaceutical drug is called an active pharmaceutical ingredient. HPAPI are  compounds used to treat diseases such as cancer, hormonal imbalances, respiratory disorders, among others. High performance active pharmaceutical ingredients (HPAPI) are the fastest growing segment of the active ingredient market. Advances in clinical pharmacology and oncology research are some of the main reasons driving the growth of the HPAPI market.

An increasing geriatric population across the globe coupled with lifestyle related diseases in the younger generation are factors that are causing an increase in cancer, diabetes, cardiovascular diseases, among others. In the case of cancer, current treatment methods such as chemotherapy have severe side effects as well as they affect the non cancerous cells. Favorable government regulations are also helping with development of the pipeline of efficient drugs which is further augmenting the HPAPI market. The fact that some of the drugs are approaching patent expiry also positively impacts the market.

High performance active pharmaceutical ingredients (HPAPI) Market

The High Performance Active Pharmaceutical Ingredients Market  market can be segmented on the basis of type of ingredient as:
  • Synthetic
  • biological 
  • Others 

The High Performance Active Pharmaceutical Ingredients market can be segmented on the basis of type of drugs as:
  • Innovative
  • generic 
  • Others 
Currently, oncology accounts for the largest share of the application market for HPAPI. Rising instances in hormonal imbalance in the femal population is a factor that makes this segment the second largest segment of the overall HPAPI market. 

In terms of applications, the High Performance Active Pharmaceutical Ingredients Market has been segmented across the following:
  • Oncology
  • anti-diabetic
  • cardiovascular
  • hormonal
  • Musculoskeletal
  • Glaucoma 
  • Others

North America currently accounts for the largest share of the HPAPI market while the asia pacific region is expected to grow at the fastest rate till the end of the forecast period considered in this report. Emerging economies in the APAC region are witnessing a rapid growth and development in the healthcare industry owing to increasing awareness levels and spending capacity of people in those countries. 

The market has been segmented based on the following geographies:
  • North America
  • South America
  • APAC
  • Europe
  • Middle East 
  • Africa

Following are just a few of the companies that are operating in the High Performance Active Pharmaceutical Ingredients Market:
  • Sanofi Aventis
  • Hospira Inc
  • Lonza Group
  • BASF AG
  • Bristol-Myers Squibb Company 
  • Novartis International AG
1. High Performance Active Pharmaceutical Ingredients – Market Overview
2. Executive Summary 
3. High Performance Active Pharmaceutical Ingredients– Market Landscape 
   3.1. Market Share Analysis
   3.2. Comparative Analysis
      3.2.1. Product Benchmarking
      3.2.2. End User Profiling
      3.2.3. Top 5 Financials Analysis
4. High Performance Active Pharmaceutical Ingredients– Market Forces
   4.1. Market Drivers 
   4.2. Market Constraints
   4.3. Market Challenges
   4.4. Attractiveness of the High Performance Active Pharmaceutical Ingredients Market 
      4.4.1. Power of Suppliers
      4.4.2. Power of Customers 
      4.4.3. Threat of New Entrants 
      4.4.4. Threat of Substitution
      4.4.5. Degree of Competition
5. High Performance Active Pharmaceutical Ingredients Market– Strategic Analysis
   5.1. Value Chain Analysis
   5.2. Pricing Analysis 
   5.3. Opportunities Analysis
   5.4. Product/Market Life Cycle Analysis
   5.5. Suppliers and Distributors
6. High Performance Active Pharmaceutical Ingredients Market – By Type of Ingredient
   6.1. Synthetic
   6.2. Biological
   6.3. Others
7. High Performance Active Pharmaceutical Ingredients Market – By Type of Drug
   7.1. Innovative
   7.2. Generic
   7.3. Others
8. High Performance Active Pharmaceutical Ingredients Market– By Application 
   8.1. Oncology
   8.2. Glaucoma
   8.3. Anti-diabetic
   8.4. Cardiovascular
   8.5. Musculoskeletal
   8.6. Hormonal
   8.7. Others
9. High Performance Active Pharmaceutical Ingredients Market– By Geography
   9.1. Introduction
   9.2. Global Study
   9.3. Americas
      9.3.1. North America 
      9.3.2. Brazil
      9.3.3. Argentina
      9.3.4. Others 
   9.4. Europe
      9.4.1. U.K.
      9.4.2. France
      9.4.3. Germany
      9.4.4. Others
   9.5. APAC
      9.5.1. China
      9.5.2. Japan
      9.5.3. India
      9.5.4. Others
   9.6. ROW
10. High Performance Active Pharmaceutical Ingredients Market– Market Entropy
   10.1. New Product Launches
   10.2. M&As, Collaborations, JVs and Partnerships
11. Company Profiles 
   11.1. Bristol-Myers Squibb Company
   11.2. Novartis International AG
   11.3. Sanofi Aventis
   11.4. Pfizer Inc.
   11.5. Lonza Group
   11.6. Novasep
   11.7. Hospira Inc.
   11.8. BASF AG
   11.9. Merck & Co., Inc.
   11.10. Sigma Aldrich Corporation
   11.11. Bayer AG
   11.12. Boehringer Ingelheim GmbH
   11.13. Lonza
   11.14. Teva Pharmaceuticals Industries Ltd.
   11.15. Others
*More than 40 Companies are profiled in this Research Report, Complete List available on Request*
"*Financials would be provided on a best efforts basis for private companies"
12. Appendix
   12.1. Abbreviations
   12.2. Sources
   12.3. Research Methodology
   12.4. Bibliography
   12.5. Compilation of Expert Insights
   12.6. Disclaimer
Please select Licence
Single User Licence:
US $4250
Corporate User Licence:
US $6250
Related Reports
0px;">Scroll